

Congress	DGPPN Congress 2022
Date	November 23 – 26, 2022
Submission deadline	June 17, 2022
Word count	1999 characters (limit: 2000 characters with spaces)

Herbert Schreiber<sup>1</sup>, Fabian Roßnagel<sup>2</sup>, Lena Beilschmidt<sup>3</sup>, Simone Braun<sup>3</sup>, Anita Kretschmann<sup>3</sup>, Arnfin Bergmann<sup>2</sup>

<sup>1</sup>*Neurological Practice Center, Ulm, Germany;*

<sup>2</sup>*NeuroTransData, Neuburg an der Donau, Germany*

<sup>3</sup>*Roche Pharma AG, Grenzach-Wyhlen, Germany;*

#### Author disclosures

H. Schreiber ([schreiber@neurologie-ulm.de](mailto:schreiber@neurologie-ulm.de)): Almirall, Biogen, Genzyme, Merck, Novartis, Roche, Teva // speakers bureau or advisory board, consulting fees, travel reimbursement; Biogen, Novartis, Teva // research grants; Biogen, Novartis, Roche // data monitoring or steering committees

F. Roßnagel ([frossnagel@neurotransdata.com](mailto:frossnagel@neurotransdata.com)): Employee of NeuroTransData GmbH

L. Beilschmidt ([lana.beilschmidt@roche.com](mailto:lana.beilschmidt@roche.com)): Employee of Roche Pharma AG

S. Braun ([simone.braun.sb1@roche.com](mailto:simone.braun.sb1@roche.com)): Employee of Roche Pharma AG

A. Kretschmann ([anita.kretschmann@roche.com](mailto:anita.kretschmann@roche.com)): Employee of Roche Pharma AG

A. Bergmann ([abergmann@neurotransdata.com](mailto:abergmann@neurotransdata.com)): has received consulting fees from advisory board/speaker/other activities for NeuroTransData; project management/clinical studies for and travel expenses from Novartis and Servier.

# Characterisation of AD patients in Germany: Descriptive analysis of real-world NTD registry data

## Background

Alzheimer's Disease (AD) is the most common neurodegenerative disease affecting more than 1.5 million people in Germany. Reliable real-world data on patient pathways and treatment patterns of AD may help to improve primary and secondary preventive strategies. This analysis aims at gaining insights into the main characteristics, diagnostics and current therapy of AD patients in Germany in daily practice using NeuroTransData (NTD) registry data.

## Methods

This retrospective analysis of NTD registry data includes patients diagnosed with AD based on ICD-10 codes relevant for AD (data cut-off October 2021). The first visit date with AD diagnosis was referred to as reference date. Latest MoCA, DemTect or MMSE scores documented within 1 year prior to reference date were employed to define subgroups by disease stage.

## Results

Within the NTD registry, data of 2,092 AD patients from 39 practices across Germany were documented. Based on AD-relevant ICD-10 codes, 2,065 patients (98.7%) were diagnosed with "unspecified AD" (G30.9). When relying on documented cognitive scores, patients were staged as normal (n=223), MCI (n=431), medium stage AD (n=179 patients), medium/late stage AD (n=411), severe late stage AD (n=103) and unknown (n=745). Most relevant comorbidities (clinical diagnosis at reference date) were subcortical vascular dementia (7.89%) and depressive episodes (6.02%). At reference date, most AD patients had been tested with the MMSE, and were treated with acetylcholinesterase inhibitors (38%) or glutamate receptor modulators (15.2%).

## Conclusion

Analysis revealed that an initial AD diagnosis in Germany is very often unspecified with respect to AD-relevant ICD-10 codes. This highlights the need for both a more precise diagnostic work-up and a revised coding system to allow precise coding. Particularly patients with subtle cognitive impairment preceding the clinical AD diagnosis are of interest to better understand the conversion from normal aging/MCI to manifest AD.